Advertisement
Advertisement
U.S. markets close in 2 hours 13 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Alzamend Neuro, Inc. (ALZN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9553-0.0246 (-2.51%)
As of 01:47PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.9799
Open0.9800
Bid0.9553 x 1000
Ask0.9667 x 800
Day's Range0.9552 - 1.0000
52 Week Range0.8010 - 4.3300
Volume153,967
Avg. Volume346,888
Market Cap91.214M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1140
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ALZN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Alzamend Neuro, Inc.
    Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
    Rating
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • InvestorPlace

    6 Penny Stocks With 1,000% Upside Potential

    Investors in penny stocks know that they are an inherently risky proposition. That goes double for any investor just getting into this market. But with great risk comes great reward. In this case, I think these are penny stocks with 1,000% upside potential. That would be a return any investor would love. First, the methodology for assessing upside potential: This is simply a measure of the current price against the target price. So, all of these stocks above could turn $1,000 into $11,000 is ana

  • Benzinga

    Alzamend Neuro Receives Positive FDA Response For Its Depression Candidate

    Alzamend Neuro Inc (NASDAQ: ALZN) has received a written response to its meeting request relating to its Type B Pre-Investigational New Drug (IND) application from the FDA. The FDA’s response provides a path for Alzamend’s planned clinical development of AL001 for bipolar disorder, major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). In Phase 1, a relative bioavailability comparison of AL001 to lithium carbonate completed in March, AL001 was shown to provide dose-normalize

  • Business Wire

    Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

    ATLANTA, July 18, 2022--Alzamend Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depression, and Post-Traumatic Stress Disorder

Advertisement
Advertisement